Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents
Simon R. Stockwell,Duncan E. Scott,Gerhard Fischer,Estrella Guarino,Timothy P. C. Rooney,Tzu-Shean Feng,Tommaso Moschetti,Rajavel Srinivasan,Esther Alza,Alice Asteian,Claudio Dagostin,Anna Alcaide,Mathieu Rocaboy,Beata Blaszczyk,Alicia Higueruelo,Xuelu Wang,Maxim Rossmann,Trevor R. Perrior,Tom L. Blundell,David R. Spring,Grahame McKenzie,Chris Abell,John Skidmore,Ashok R. Venkitaraman,Marko Hyvönen
DOI: https://doi.org/10.1021/acs.jmedchem.4c01165
IF: 8.039
2024-08-30
Journal of Medicinal Chemistry
Abstract:Aurora A kinase, a cell division regulator, is frequently overexpressed in various cancers, provoking genome instability and resistance to antimitotic chemotherapy. Localization and enzymatic activity of Aurora A are regulated by its interaction with the spindle assembly factor TPX2. We have used fragment-based, structure-guided lead discovery to develop small molecule inhibitors of the Aurora A-TPX2 protein-protein interaction (PPI). Our lead compound, CAM2602, inhibits Aurora A:TPX2...
chemistry, medicinal
What problem does this paper attempt to address?